COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions by Ungaro, Ryan C. et al.
COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical 
Recommendations, and Unanswered Questions 
Ryan  C. Ungaro1, Michael D. Kappelman2, David T. Rubin3, Jean-Frederic Colombel1 
 
1. The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount 
Sinai, New York, NY 
2. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC 
3. University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL 
 
Word Count: 2,162 
 
Corresponding Author 
Ryan  C. Ungaro MD MS 
Assistant Professor of Medicine 
The Henry D. Janowitz Division of Gastroenterology 
Icahn School of Medicine at Mount Sinai 
1 Gustave L. Levy Place 
New York, NY 10029 
ryan.ungaro@mssm.edu 
 
Conflicts of Interest 
RCU has served as a consultant and/or advisory board member for Bristol Myers Squibb, Eli 
Lilly, Janssen, Pfizer and Takeda. He has received research support from AbbVie, Boehringer 
Ingelheim and Pfizer. MDK has consulted for Abbvie, Janssen, Pfizer, and Takeda, is a 
shareholder in Johnson & Johnson, and has received research support from Pfizer, Takeda, 








Arenapharm. DTR has received grant support from Abbvie, Genentech/Roche, Janssen 
Pharmaceuticals, Prometheus Laboratories, Shire, and Takeda; and has served as a consultant 
for Abbvie, Abgenomics, Allergan Inc., Biomica, Boehringer Ingelheim Ltd., Bristol-Myers 
Squibb, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, 
Genentech/Roche, Gilead Sciences, GlaxoSmithKline Services, Ichnos Sciences S.A., InDex 
Pharmaceuticals, Janssen Pharmaceuticals, Lilly, Narrow River Mgmt, Pfizer, Prometheus 
Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Jean-Frederic Colombel  has received 
research grants from AbbVie, Janssen Pharmaceuticals and Takeda; has received payment for 
lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring 
Pharmaceuticals, Shire, Takeda and Tillots; has received consulting fees from AbbVie, Amgen, 
Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene 
Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative 
Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech 
Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, 
Viela bio; and hold stock options in Intestinal Biotech Development. 
Funding 
















On March 11, 2020 the World Health Organization declared the 2019 novel coronavirus (severe 
acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) epidemic a global pandemic.1 
Physicians, scientists, and patients scrambled to gain an understanding of the implications of 
this dire situation, and societies and organizations tried to provide guidance of best practices 
and precautions. In the inflammatory bowel disease community (IBD), the International 
Organization for the study of IBD (IOIBD) convened their expert members and performed a 
RAND panel assessment to develop recommendations for patients and providers.2 Others 
developed an international open registry to collect data about patients with IBD who developed 
Coronavirus Disease (COVID-19), the Surveillance Epidemiology of COVID-19 Under Research 
Exclusion (SECURE-IBD), in order to collect evidence on how COVID-19 impacted  IBD  
patients. To date, SECURE-IBD has amassed 3,493 cases with outcomes3 and published initial 
analyses.4–6 In addition, there were multiple articles published with individual or multi-center 
experiences, city or regional experiences, and many case reports about IBD or immune-
mediated disease outcomes.7–14 Separately, there was significant activity by translational and 
basic scientists working to define and describe the pathophysiology of SARS-CoV-2 infections.  
 
Early reports and expert opinions were necessary to guide the world in their approach to this 
unprecedented global problem, but the substantial amount of progress made warrants an 
updated review and discussion. In this commentary we outline the emerging evidence and 
lessons learned about COVID-19 and the IBD population, enumerate unanswered questions 
that remain to be addressed, and provide practical recommendations. 
 
Are Patients with IBD At Increased Risk of Contracting SARS-CoV-2? 
Initial expert opinion from the IOIBD at the start of the pandemic suggested that IBD patients 








biologic plausibility that IBD patients may have differential risk for contracting SARS-CoV-2 as 
the receptor for the virus, angiotensin converting enzyme receptor 2 (ACE2), appears to be 
differentially expressed in inflamed IBD mucosa with upregulation in the colon but 
downregulation in the small intestine.15–17 SARS-CoV-2 receptor expression also appears to be 
impacted by IBD medications, with infliximab notably being associated with decreased ACE2.17  
 
Recent reports from large cohorts have provided evidence that IBD patients do not appear to be 
at increased risk of COVID-19. IBD patients in the US Veterans Affairs (VA) healthcare system 
had a similar incidence of confirmed SARS-CoV-2 compared to the general VA population 
(0.23% versus 0.20%, p=0.29).18 Similar results were seen in two European population-based 
cohorts. The incidence of COVID-19 in patients with IBD in the Netherlands compared to the 
general population was comparable (287.6 versus 330.0 per 100,000 patients, p=0.15).19 A 
population based cohort study from Denmark found that patients with IBD may actually have 
lower prevalence of SARS-CoV-2 than the general population (2.5% versus 3.7%, p<0.01).20 
Further, patients with IBD receiving immunosuppressive medications do not appear to be at 
increased risk of contracting COVID-19.21,22 Humoral immune response against SARS-Cov2 
leads to the production of antibodies of different classes and serological testing is another tool 
to assess SARS-Cov2 infection prevalence.23 Studies from Italy and Germany showed a similar 
SARS-Cov2 seroprevalence in IBD patients treated with biological therapy as in general 
population.24    
 
The sum of these data suggests that IBD patients are not at higher risk of contracting SARS-
CoV-2 than the general population. However, it is important to note that these findings may be 
influenced by social behaviors during the pandemic, in particular the potential for patients with 










Are Patients with IBD Who Develop COVID-19 at Increased Risk of Adverse Outcomes? 
Emerging evidence suggests that when patients with IBD develop COVID-19, the course of 
illness may be somewhat more severe.  The initial report from SECURE-IBD calculated age and 
sex-standardized mortality ratios (SMRs), comparing patients with IBD reported to the database 
to  general population data reported from China, Italy, and the United States.  Observed SMRs 
varied from 1.45 to 1.76, suggesting a 50% higher COVID-related mortality in patients with IBD; 
however, these findings were not statistically significant due to 95% confidence intervals 
crossing one.4  As of December 6th, 2020, a total of 3,493 cases have been reported to 
SECURE-IBD and while the magnitude of the earlier findings remain unchanged, the increased 
mortality rate is now statistically significant.  For example, the U.S. SMR is 1.4 (95% CI 1.1-1.7). 
Although the observed excess mortality among IBD patients may be due to reporting bias, 
potential drivers of COVID-19 mortality among IBD patients may include chronic intestinal 
inflammation, non-IBD comorbidities, and exposure to corticosteroids and other 
immunosuppressive medications.  In contrast, a separate EHR-based study across 31 
institutions compared 232 patients with IBD diagnosed with COVID-19 to propensity matched 
controls without IBD and found no differences in COVID-19 hospitalization or mortality.25 
 
Among patients with IBD, as in the general population, key risk factors for more severe COVID-
19 infection appear to be advancing age and the presence of comorbid conditions.  In the initial 
report from SECURE-IBD, the primary outcome (ICU/ventilator/death) was observed in 37 (7%) 
of 525 patients overall.  However, among patients over 60 years of age 10/101 (20%) 
experienced this outcome versus 0 of 29 pediatric cases (<20 years).4  Older age (>65 years) 
was also demonstrated to be significantly associated with COVID-19 mortality in an Italian multi-
center cohort (OR 19.6, 95% CI 2.95-130.6).8  Additionally, the number of non-IBD comorbidities 








Comorbidity Index >1 was associated with increased mortality (OR 16.7, 95% CI 1.8-153.9).  
Similarly, a Dutch nationwide cohort study identified >1 comorbidity as an independent risk 
factor for hospitalization (OR 4.20, 95%CI 1.58-11.17).19 In SECURE-IBD, having ≥2 
comorbidities was associated with 3-fold risk of requiring ICU, ventilator, or death (aOR, 2.9, 
95% CI,1.1–7.8).4  Aside from age and non-IBD comorbidities, associations between other 
demographic and clinical characteristics (sex, IBD type, IBD disease activity) and the severity of 
COVID-19 have been inconsistent or relatively small in magnitude.4,8,19   
 
In terms of the risk of IBD medications, current or recent use of systemic corticosteroids to treat 
IBD at the time of COVID-19 infection has been consistently associated with more severe 
outcomes, despite emerging data suggesting that dexamethasone use in severe COVID-19 may 
reduce mortality.4,8,25  We believe these are two different distinct clinical scenarios.  Use of 
steroids in patients with IBD at or prior to infection may allow a greater degree of viral replication 
early in the course of illness while treatment of later-stage infections with prednisone may blunt 
the cytokine storm characteristic of more severe cases with respiratory failure. In addition, data 
have suggested that mesalamines may be associated with an increased risk of severe COVID-
19.4,5 However, the effect size of this association has attenuated with time and given the 
unexpected nature of this finding and potential for unmeasured confounding, requires further 
investigation.4,5 Reassuringly, anti-tumor necrosis factor (TNF) therapy has not been associated 
with more severe COVID-19. An analysis of 600 cases of individuals with rheumatic diseases 
demonstrated that anti-TNF therapy was associated with a reduced odds of hospitalization (OR 
0.40, 95% CI 0.19 to 0.81).26  In an analysis of nearly 1500 cases reported to SECURE-IBD, 
Ungaro et al demonstrated reduced risk of severe COVID-19 in patients treated with anti-TNF 
monotherapy versus anti-TNF in combination with thiopurine or thiopurine monotherapy.5 More 
data are needed to fully evaluate the safety of other classes of IBD medications, though to date 








tofacitinib.5,10 As a side note, there are active trials of anti-TNF as well as JAK inhibitors  
therapies (tofacitinib and baricitinib) as treatments for COVID-19.27–29 
 
Are Gastrointestinal Symptoms of COVID-19 Common in Patients with IBD? 
Early in the pandemic, it was appreciated that digestive symptoms occurred in some patients 
with COVID-19, and this has obvious implications for patients with IBD. In the original report of 
COVID-19 from Wuhan, China, 48% of the hospitalized patients had digestive symptoms, which 
were most often diarrhea and abdominal pain, although most of these patients also had 
concurrent respiratory symptoms and fever.30 Subsequent studies have confirmed these 
symptoms as well as nausea and vomiting, with the duration of diarrhea (defined differently) 
varying from 1 to 14 days.31–33 The Centers for Disease Control and Prevention subsequently 
added digestive symptoms of anosmia, diarrhea, nausea and vomiting to the list of presenting 
symptoms associated with COVID-19.34 The presence of these symptoms suggested the 
possibility of viral entry through the intestinal mucosa, further supported by prior research 
identifying expression of ACE2, the site of viral binding and endocytosis, throughout the 
intestinal tract.17 Also of interest is whether the presence of digestive symptoms predicts the 
severity of COVID-19. A pooled analysis of multiple studies demonstrated that abdominal pain 
was associated with increased odds of severe COVID-19 (OR 3.93 [95% CI 1.64–9.38]), but 
there were only marginally increased odds with nausea or vomiting (OR 1.65 [95% CI 1.06–
2.57]), and no association with diarrhea.35 However there are conflicting data as a recent report 
on hospitalized COVID-19 patients observed that those with digestive symptoms on admission 
had lower mortality.36 The question of whether there is fecal-oral transmission of SARS-CoV2 
also has not been resolved.  
 








Detailed studies of the antibody response to SARS-CoV-2 in patients with IBD will be crucial not 
only to understanding the immune response to virus with implications for vaccine research but 
also because of the possibility of emergence of cross-reactive antibodies which could contribute 
to long term complications of COVID-19. The vast majority of patients with mild-to-moderate 
COVID-19 experience robust IgG antibody responses against the viral spike protein and have 
titers that are stable for approximately 5 months which significantly correlate with SARS-CoV-2 
neutralization.37 However, it is still unclear if the humoral response to SARS-CoV-2 will be 
attenuated in IBD patients. Data from Germany showed a lower seroprevalence of anti-SARS-
CoV-2 antibodies in immune-mediated disease patients on cytokine inhibitors compared with 
general population although this was not confirmed in a recent study in which biological therapy, 
including vedolizumab, did not prevent the mounting of an efficient humoral response to SARS-
CoV2.9,24 Longitudinal seroprevalence studies are necessary. Another aspect to consider is 
whether the virus may impact the host immune response by inducing autoantibodies, triggering 
cross-reactive antibodies, or altering IgA-microbe interactions in the gut. Studies have 
highlighted the possibility that COVID-19 could induce pathogenic autoantibody formation both 
in adult and pediatric patients with severe COVID-19 and in COVID-19 patients who developed 
neuropathology.38 These will be important questions to consider as we address the impact of 
SARS-CoV-2 on IBD. 
 
Practical Recommendations 
The accumulating evidence suggests that patients with IBD may be at increased risk of adverse 
outcomes, particularly patients who are older, have comorbidities, or are undergoing treatment 
with systemic corticosteroids.  We advise that patients should continue on prescribed 
medications with the exception of corticosteroids which should be tapered off or to lowest 
possible dose. In addition, de-escalation of combination therapy with thiopurine and anti-TNF 








severe COVID-19 and mesalamines requires further data, we would recommend limiting their 
use in situations of low clinical value (Crohn’s disease and after escalating to biologic therapy in 
ulcerative colitis). Given that lack of adverse impact of biologics on COVID-19 outcomes, 
patients with asymptomatic or mild COVID-19 may be able to either continue or avoid prolonged 
holding of needed medications. A summary of clinical implications and recommendations is 
provided in Table 1.  
 
What are the Unanswered Questions about COVID-19 and Patients with IBD? 
Despite prolific research regarding COVID-19 and IBD over the past six months, several critical 
research gaps remain. Observations on impact  medications such as aminosalicylates from the 
SECURE-IBD registry should be validated in large population-based cohorts. It will also be 
critical to understand the degree of immunity and long-term seroprotection to SARS-CoV-2, and 
how immunity is affected by the inflammatory disease process and by the  treatments for IBD.  
Studies on the impact of COVID-19 on the natural history of IBD and possible emergence of de 
novo IBD and other immune-mediated diseases clearly are needed.  In addition, it will be 
essential to evaluate vaccine effectiveness and safety among patients with IBD and how these 
are impacted by the type and degree of immune suppression, given that patients with IBD and 
other immune mediated conditions have been excluded from clinical vaccine trials. 
 
Conclusion  
The IBD community has made significant strides in developing an evidence base with which to 
inform patients and providers during the COVID-19 pandemic. Based on the current literature 
and this update, we conclude that for the most part, patients with IBD are not at increased risk 
for SARS-CoV-2 infection compared with the general population and, with the exception of 
steroids, medications that treat IBD are not associated with clear harm in the setting of COVID-
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Table 1. Summary of New Knowledge and Clinical Implications/Recommendations 
New Knowledge Clinical Implication / Recommendation  
IBD patients including those on biological 
therapy do not appear to be at increased risk 
of contracting SARS-CoV-2 compared to the 
general public 
Standard precautions (wear a mask, wash 
your hands, and social distance) are 
sufficient for most IBD patients 
Age and co-morbidities in addition to IBD 
confer increased risk of severe COVID-19 
As with other non-IBD populations, older age 
(>65) and the presence of non-IBD 
comorbidities should be used to risk stratify 
patients with IBD and inform 
clinical/treatment decisions as well as lifestyle 
decisions such as work, school, and the 
degree of physical distancing (“shielding”).   
 
Systemic corticosteroids significantly 
increase the risk of severe COVID-19 
Corticosteroid use to treat IBD should be 
minimized to the extent reasonably possible 
throughout the pandemic. 
Combination therapy and thiopurine 
monotherapy are associated with severe 
COVID-19 compared to anti-TNF 
monotherapy, especially in older patients. 
In selected high-risk patients (older, multiple 
comorbidities), withdraw of combination 
therapy in favor of anti-TNF monotherapy 
should be considered, particularly in patients 
who have achieved a durable deep 
remission. 








small molecules do not appear to be 
associated an increased risk of severe 
COVID-19.   
associated with substantial COVID-19 safety 
signals, and hence should be continued 
during the pandemic.   
 
Prior recommendations to temporarily hold 
biologics and other IBD therapies in the 
setting of acute COVID-19 infection should 
be reconsidered, given paucity of data 
suggesting a harmful effect of such 
treatments. 
Mesalamines may be associated with an 
increased risk of severe COVID-19 
We in general would not avoid use of 
mesalamines but, until further data are 
available to confirm or refute this observation, 
recommend avoiding in situations where their 
efficacy is limited (Crohn’s disease and after 
escalating to a biologic in ulcerative colitis).  
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